Navigation Links
BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
Date:11/8/2012

ersify its existing portfolio. 

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence.  BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Health Solutions.  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
2. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
4. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
5. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
6. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
(Date:6/30/2015)... ... June 30, 2015 , ... Family and professional ... Education Symposium on November 9, 2015 at the Hyatt Regency Denver Tech Center ... with Kim and Ashley Campbell, the wife and daughter of singer Glen Campbell, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Allied Anesthesia ... Allied’s Fullerton division volunteered to help provide free outpatient procedures to some of ... at St. Jude Medical Center. , The event was coordinated by AccessOC, ...
(Date:6/30/2015)... NY (PRWEB) , ... June 30, 2015 , ... ... newest oncology centers are partnering to improve access to cancer prevention, screening and ... Cancer Center (LCC) have announced an affiliation that will see Roswell Park faculty ...
(Date:6/30/2015)... ... 2015 , ... Board certified otolaryngologist Dr. Marcelo B. Antunes ... , Dr. Antunes is a fellowship trained facial plastic surgeon with ... to performing cosmetic and reconstructive surgery on the face, he enjoys treating patients ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... device market research, has launched a new reimbursement insurance policy tracking and analysis ... to receive US insurance policy and rate updates in real-time from hundreds of ...
Breaking Medicine News(10 mins):Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2
... and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that ... tablets has been submitted to the U.S. Food ... with hepatocellular carcinoma (HCC), the most common form of ... more than 50 countries for the treatment of advanced ...
... at the J. Craig Venter Institute (JCVI) today announced ... them to transform one type of bacteria into another ... ,The work, published online in the journal Science, by ... and techniques used to change one bacterial species, Mycoplasma ...
... similar effect to antidepressants on depression. Exercise stimulates new ... scientific reports, she has searched for the underlying biological ... of therapy for depression and has also compared it ... ,The experiment studies were conducted on rats. The results ...
... customers shisha water pipes to smoke tobacco are waging an ... comes into force in England on Sunday. ... are variously called, dozens of restaurants will lose their main ... activity disappear. ,"It's a disaster, we don't know ...
... withdrawn an application for regulatory approval for its anti-obesity drug ... of experts from the US Food and Drug Administration concluded ... rimonabant by the company, was unsafe and should not be ... towards submitting the rimonabant file to the FDA at a ...
... in a name, one might rhetorically ask. But Malaccan state ... bat virus after their region. And now the virus will ... Malaysian scientists announced last week they discovered a new virus ... humans. They called it the Melaka Virus, using the name ...
Cached Medicine News:Health News:Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 3Health News:Mealaka Virus Will Have a New Name 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: